Provided in the present invention are a compound as shown in formula I, various crystal forms thereof, a hydrate, a solvate or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition. The compound of the present invention can effectively treat Alzheimer's disease or Down's syndrome, especially cognitive function impairment caused by Alzheimer's disease or Down's syndrome. Also disclosed in the present invention is use of a ubiquitin specific protease USP25 encoded and expressed by chromosome 21 for preventing, treating or ameliorating Alzheimer's disease or Down's syndrome.

##STR00001##

Provided in the present invention are a compound as shown in formula I, various crystal forms thereof, a hydrate, a solvate or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition. The compound of the present invention can effectively treat Alzheimer's disease or Down's syndrome, especially cognitive function impairment caused by Alzheimer's disease or Down's syndrome. Also disclosed in the present invention is use of a ubiquitin specific protease USP25 encoded and expressed by chromosome 21 for preventing, treating or ameliorating Alzheimer's disease or Down's syndrome.

##STR00001##

The present invention provides compounds of Formula (I),

##STR00001##

pharmaceutical compositions comprising these compounds and methods of using these compounds to provides a method of modulating a HSD17B13 protein for treatment of metabolic disease or liver condition, The present invention relates generally to compounds and pharmaceutical compositions useful as 17β-HSD13 inhibitors. Specifically, the present invention relates to compounds useful as inhibitors of 17β-HSD13 and methods for their preparation and use.

The present invention provides compounds of Formula (I),

##STR00001##

pharmaceutical compositions comprising these compounds and methods of using these compounds to provides a method of modulating a HSD17B13 protein for treatment of metabolic disease or liver condition, The present invention relates generally to compounds and pharmaceutical compositions useful as 17β-HSD13 inhibitors. Specifically, the present invention relates to compounds useful as inhibitors of 17β-HSD13 and methods for their preparation and use.

Therapeutic compositions comprising one or more agents that inhibit CXXC5-DVL interface, and methods of administering those therapeutic compositions to model, treat, reduce resistance to treatment, prevent, and diagnose a condition/disease associated with a metabolic disease or a related clinical condition thereof, are disclosed.

The present invention is directed to novel compounds of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof. Pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, are also described. The invention is also directed to use of the compounds of Formula (I) for treating a condition in a mammal associated with AhR imbalance, such as an inflammatory disease or disorder.

The present invention is directed to novel compounds of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof. Pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, are also described. The invention is also directed to use of the compounds of Formula (I) for treating a condition in a mammal associated with AhR imbalance, such as an inflammatory disease or disorder.

The present invention is directed to novel compounds of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof. Pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, are also described. The invention is also directed to use of the compounds of Formula (I) for treating a condition in a mammal associated with AhR imbalance, such as an inflammatory disease or disorder.

The present invention is directed to novel compounds of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof. Pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, are also described. The invention is also directed to use of the compounds of Formula (I) for treating a condition in a mammal associated with AhR imbalance, such as an inflammatory disease or disorder.

Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.